[Scopio in PR Newswire] Scopio Labs receives fourth FDA clearance, elevating digital morphology with enhanced AI-powered RBC and platelet capabilities

TEL AVIV, Israel, July 10, 2025 /PRNewswire/ — Scopio Labs, a trailblazer in Full-Field Digital Cell Morphology, today announced another significant milestone: its fourth U.S. Food and Drug Administration (FDA) clearance (K243144). This latest clearance introduces powerful new Decision Support System (DSS) features to its X100 and X100HT platforms and Peripheral Blood Smear (PBS) Application, further transforming the way laboratories analyze red blood cell (RBC) morphology and identify platelet clumps in peripheral blood smears.

Read more here.